NeuroMetrix to Present at the LD Micro Invitational Conference on December 6, 2016
November 30 2016 - 7:00AM
Business Wire
NeuroMetrix, Inc. (NASDAQ:NURO, NUROW) today announced
that Shai N. Gozani M.D., Ph.D., President and Chief
Executive Officer, is scheduled to speak at the upcoming LD Micro
Invitational at the Luxe Sunset Bel Air Hotel in Los
Angeles, CA. Dr. Gozani intends to provide an update on
the Company's business activities including the
Quell® Wearable Pain Relief Technology™.
The NeuroMetrix presentation is scheduled for Tuesday,
December 6, 2016, at 8:00 a.m. Pacific Time (11:00
a.m. Eastern). A live audio webcast will be available on the
investor relations section of the corporate website
- http://www.NeuroMetrix.com/. This webcast will be archived
after the live event.
About Quell
Quell utilizes NeuroMetrix's patented neurostimulation
technology to provide widespread relief from chronic pain. The
advanced wearable device is lightweight and can be worn during the
day while active, and at night while sleeping. It has been cleared
by the FDA for treatment of chronic pain without a
prescription. In a recent study, 81% of Quell users reported an
improvement in their chronic pain. Quell was recently named
"Winner" in the Wearable Tech category at the SXSW Interactive
Innovation Awards. It is available for purchase
at QuellRelief.com, selected retailers and healthcare
professionals.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap space. What started out as a
newsletter highlighting unique companies has transformed into an
event platform hosting several influential conferences annually
(Invitational, Summit, and Main Event). In 2015, LDM launched the
first pure microcap index (the LDMi) to exclusively provide
intraday information on the entire sector. For more information,
visit www.ldmicro.com.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven
healthcare company combining bioelectrical and digital medicine to
address chronic health conditions including chronic pain, sleep
disorders, and diabetes. The company's lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain.
Quell is integrated into a digital health platform that helps
patients optimize their therapy and decrease the impact of chronic
pain on their quality of life. The company also markets DPNCheck®,
a rapid point-of-care test for diabetic neuropathy, which is the
most common long-term complication of Type 2 diabetes. The company
maintains an active research effort and has several pipeline
programs, including a therapeutic device for restless leg syndrome.
The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health
Sciences and Technology in 1996. For more information, please
visit www.NeuroMetrix.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161130005172/en/
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief
Financial Officerneurometrix.ir@neurometrix.com
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Aug 2024 to Sep 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Sep 2023 to Sep 2024